# Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

> **NCT06430502** · NA · RECRUITING · sponsor: **Wuxi People's Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Cancer
- PD-L1 Gene Mutation

## Interventions

- **BIOLOGICAL:** Tumor Treatment Vaccine; PD-1/L1 inhibitors

## Key facts

- **NCT ID:** NCT06430502
- **Lead sponsor:** Wuxi People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430502, "Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06430502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*